EC nod for Chiesi Lojuxta for pediatric HoFH: what it means for pharma

EC nod for Chiesi Lojuxta for pediatric HoFH: what it means for pharma

The European Commission has expanded Lojuxta's indication to include children aged 5 years and older with homozygous familial hypercholesterolemia. This analysis covers the regulatory shift, implications for Chiesi's rare disease franchise, and what investors and BD teams should monitor next.

IntelligenceRegulatory Impact▾

European Commission (EC) decisions frame this story. Regulatory relevance is high for rare disease, with Lojuxta most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• EC approval expands Lojuxta's label to children aged 5+ with HoFH, a significant regulatory milestone that addresses a high unmet need in pediatric rare disease.
• Chiesi strengthens its rare disease portfolio, building on recent acquisitions like the KalVista Pharma buyout, signaling a focused strategy in orphan drug territories.
• Competitive dynamics shift: Lojuxta now directly competes with Regeneron's evinacumab in the pediatric HoFH space, setting up a head-to-head battle between oral and injectable therapies.
• Investors should watch EU market access decisions and potential US pediatric filing as the next major catalysts for the asset.

IntelligenceCompetitive Intelligence▾

Chiesi are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

The development

On 6 June 2026, the European Commission granted approval for Chiesi's Lojuxta (lomitapide) for the treatment of children aged 5 years and older with homozygous familial hypercholesterolemia (HoFH). The decision followed a positive opinion from the Committee for Medicinal Products for Human Use earlier in 2026. Lojuxta, an oral microsomal triglyceride transfer protein (MTP) inhibitor, had previously been approved only for adult HoFH patients. The pediatric expansion addresses a high unmet need, as HoFH often presents in childhood and leads to accelerated atherosclerosis without aggressive lipid-lowering therapy.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for rare disease. Expect implications for pricing, access, and launch sequencing.

What the pediatric expansion means for Chiesi's rare disease strategy

This approval fits squarely into Chiesi's broader push to build a rare disease franchise. The company has been on an acquisition tear, most recently agreeing to buy KalVista Pharmaceuticals in late April 2026. That deal brought in a late-stage asset for hereditary angioedema, complementing Lojuxta's position in lipid disorders. For BD teams, the pediatric nod makes Lojuxta a more attractive asset for out-licensing in territories where Chiesi lacks a direct commercial footprint. The drug's orphan designation in the EU already provides market exclusivity, and adding a pediatric indication extends the commercial runway and raises the barrier for generic entry.

The revenue upside from the pediatric population is small in absolute patient numbers—HoFH affects roughly 1 in 300,000 people—but the economics are driven by orphan drug pricing. Lojuxta already commands a premium in the adult indication, and the pediatric label allows Chiesi to capture patients earlier in their treatment journey, potentially locking in lifetime therapy. Investors should watch how national pricing authorities in Germany, France, and the UK assess the incremental value of the pediatric indication during the next round of Health Technology Assessments.

IntelligenceStrategic Takeaways▾

EC approval expands Lojuxta's label to children aged 5+ with HoFH, a significant regulatory milestone that addresses a high unmet need in pediatric rare disease. Chiesi strengthens its rare disease portfolio, building on recent acquisitions like the KalVista Pharma buyout, signaling a focused strategy in orphan drug territories. Competitive dynamics shift: Lojuxta now directly competes with Regeneron's evinacumab in

Competitive landscape: Lojuxta vs. evinacumab

The approval intensifies competition with Regeneron's evinacumab, an injectable ANGPTL3 inhibitor approved for HoFH in both adults and children. Evinacumab has the advantage of a different mechanism of action—blocking ANGPTL3 rather than inhibiting MTP—and it does not carry the same hepatic fat accumulation risk that has historically limited Lojuxta's uptake. However, Lojuxta is oral, a meaningful differentiator in a pediatric population where families may prefer to avoid regular intravenous infusions. Analysts have previously flagged that evinacumab could face pricing pressure, and the emergence of a directly competing oral option may accelerate that trend.

The real battleground will be in the US. Lojuxta's US rights were previously held by Amryt Pharma, which expanded the drug's license eastward into new territories in 2018. Chiesi has not yet disclosed a timeline for filing a pediatric supplement with the FDA, but the EU approval provides a strong data package to support that submission. A US pediatric label would put Lojuxta in direct competition with evinacumab in the world's largest pharmaceutical market, where HoFH treatment costs can exceed $500,000 annually per patient.

IntelligenceEvidence Quality▾

Grounded in 1 regulatory source and 1 peer-reviewed source.

What to watch next: market access, gene therapy, and the pipeline

The immediate catalyst is pricing and reimbursement. The EU approval is a regulatory green light, but it does not guarantee broad payer coverage. National health technology assessment bodies in Germany (IQWiG), France (HAS), and England (NICE) will each evaluate the pediatric indication independently. Chiesi will need to generate real-world evidence on long-term safety in children, particularly regarding hepatic steatosis, which is a known class effect of MTP inhibitors.

Beyond the near term, the HoFH treatment paradigm is evolving. Gene therapy approaches are in preclinical development, and while they are years away from market, they could eventually disrupt the oral and injectable drug market. For now, Lojuxta's pediatric approval gives Chiesi a foothold in a patient population that has few treatment options. The drug's mechanism of action and clinical profile are well characterized, and the pediatric data submitted to the EMA should satisfy most regulatory questions for other jurisdictions.

For investors and BD teams, the key milestones to track are: (1) pricing decisions in the top five EU markets by Q4 2026, (2) any FDA submission for pediatric use by mid-2027, and (3) competitive clinical data from Regeneron's evinacumab in younger pediatric cohorts. Chiesi's rare disease pipeline, bolstered by the KalVista acquisition and now by the Lojuxta label expansion, is starting to look like a serious challenger to established rare disease players.

Frequently Asked Questions

Related profiles

• LOJUXTA